- Home
- ASGN vs TARS Comparison
ASGN vs TARS Comparison
Compare ASGN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASGN
- TARS
- Stock Information
- Founded
- ASGN 1985
- TARS 2016
- Country
- ASGN United States
- TARS United States
- Employees
- ASGN N/A
- TARS N/A
- Industry
- ASGN Professional Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- ASGN Consumer Discretionary
- TARS Health Care
- Exchange
- ASGN Nasdaq
- TARS Nasdaq
- Market Cap
- ASGN 2.1B
- TARS 1.7B
- IPO Year
- ASGN 1992
- TARS 2020
- Fundamental
- Price
- ASGN $47.38
- TARS $70.87
- Analyst Decision
- ASGN Hold
- TARS Strong Buy
- Analyst Count
- ASGN 6
- TARS 7
- Target Price
- ASGN $60.00
- TARS $67.14
- AVG Volume (30 Days)
- ASGN 606.7K
- TARS 665.9K
- Earning Date
- ASGN 10-22-2025
- TARS 11-12-2025
- Dividend Yield
- ASGN N/A
- TARS N/A
- EPS Growth
- ASGN N/A
- TARS N/A
- EPS
- ASGN 3.15
- TARS N/A
- Revenue
- ASGN $4,004,900,000.00
- TARS $295,521,000.00
- Revenue This Year
- ASGN N/A
- TARS $137.28
- Revenue Next Year
- ASGN $2.42
- TARS $42.84
- P/E Ratio
- ASGN $14.88
- TARS N/A
- Revenue Growth
- ASGN N/A
- TARS 254.45
- 52 Week Low
- ASGN $45.10
- TARS $35.34
- 52 Week High
- ASGN $101.66
- TARS $71.11
- Technical
- Relative Strength Index (RSI)
- ASGN 44.11
- TARS 76.85
- Support Level
- ASGN $45.10
- TARS $66.79
- Resistance Level
- ASGN $49.30
- TARS $71.15
- Average True Range (ATR)
- ASGN 1.40
- TARS 2.77
- MACD
- ASGN -0.04
- TARS 0.96
- Stochastic Oscillator
- ASGN 54.05
- TARS 97.88
About ASGN ASGN Incorporated
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.